Recall all batches of Andexxa 200 mg powder for solution for infusion produced by Baxter pharmaceuti
2026-04-20
SFDA has issued a recall all batches of Andexxa 200 mg powder for solution for infusion due to The potential risks associated with the use of the product outweigh its anticipated benefits, as the scientific evaluation of the available evidence and data has demonstrated an increased risk of thrombotic events associated with its use compared to the available therapeutic alternatives.
SFDA has issued a recall all batches of Andexxa 200 mg powder for solution for infusion due to The potential risks associated with the use of the product outweigh its anticipated benefits, as the scientific evaluation of the available evidence and data has demonstrated an increased risk of thrombotic events associated with its use compared to the available therapeutic alternatives.
评论与建议
如对政府服务有任何咨询或意见,请填写所需信息。